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Abstract:  Chemokine  signaling  is  a  well-known  agent  of  autoimmune  disease,  HIV 
infection, and cancer. Drug discovery efforts for these signaling molecules have focused on 
developing inhibitors targeting their associated G protein-coupled receptors. Recently, we 
used  a  structure-based  approach  directed  at  the  sulfotyrosine-binding  pocket  of  the 
chemokine CXCL12, and thereby demonstrated that small molecule inhibitors acting upon 
the chemokine ligand form an alternative therapeutic avenue. Although the 50 members of 
the chemokine family share varying degrees of sequence homology (some as little as 20%), 
all  members  retain  the  canonical  chemokine  fold.  Here  we  show  that  an  equivalent 
sulfotyrosine-binding pocket appears to be conserved across the chemokine superfamily. 
We  monitored  sulfotyrosine  binding  to  four  representative  chemokines  by  NMR.  The 
results suggest that most chemokines harbor a sulfotyrosine recognition site analogous to 
the cleft on CXCL12 that binds sulfotyrosine 21 of the receptor CXCR4. Rational drug 
discovery efforts targeting these sites may be useful in the development of specific as well 
as broad-spectrum chemokine inhibitors. 
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1. Introduction 
The  normal  function  of  chemokines  is  to  direct  the  migration  of  cells  during  development, 
inflammation,  and  hematopoietic  stem  cell  mobilization.  As  chemokines  are  secreted  into  the 
extracellular  space,  they  bind  to  glycosaminoglycans  present  on  the  exterior  of  most  cells,  and 
establish a concentration gradient. Cells that express the G protein-coupled receptor (GPCR) specific 
for that chemokine migrate toward the origin of secretion. When the ability to traffic cells is hijacked, 
the chemokine network can maintain and coordinate many disease states. Chemokine signaling has 
been implicated in various autoimmune diseases, such as: multiple sclerosis, rheumatoid arthritis, and 
atherosclerosis  (as  reviewed  by  [1–3]).  Though  canonically  associated  with  directing  cancer  
metastases [4], the role of chemokines in tumor progression has been expanded to both growth and 
neovascularization (reviewed by [5]). 
Chemokine  signaling  has  been  the  target  of  drug  discovery  efforts  almost  since  the  initial 
identification of chemokines. These efforts  have tried to  identify small molecule therapeutics  that 
target the seven transmembrane region of the receptors. However, the binding and activation of the 
chemokine receptor is a two-step process in which the N-terminus first binds the chemokine and then 
the chemokine activates the receptor by inserting its N-terminus into the transmembrane domain [6,7]. 
High affinity chemokine binding and recognition requires that the N-terminal region of the receptor be 
post-translationally modified by O-sulfation at specific tyrosine residues. Protein sulfation is catalyzed 
by two tyrosylprotein sulfotransferases (TPST-1 and -2) located in the trans-Golgi network [8]. All 
currently known chemokine receptors contain one or more tyrosines in the N-terminal region and the 
majority of these receptors are predicted to be sulfated using various algorithms. Although a precise 
recognition sequence has yet to be identified, the presence of one or more nearby acidic residues is 
strongly correlated with tyrosine sulfation by the TPSTs [9]. However, some prediction algorithms, 
like Sulfinator [10], do not predict sulfation at known sites, like sulfotyrosine (sTyr) 7 and 12 of 
CXCR4.  Furthermore,  because  of  the  labile  nature  of  this  modification,  sulfation  sites  have  been 
experimentally confirmed for only five of the chemokine receptors: CXCR3, CXCR4, CCR2b, CCR5, 
and CX3CR1 [11–15]. Sequence alignment of chemokine receptors demonstrates the presence of a 
tyrosine residue approximately ten amino acids N-terminal to a conserved cysteine [9,16]; in most 
cases, this residue is predicted as an O-sulfation site. 
The molecular details of how chemokines recognize this conserved sulfotyrosine have only been 
determined for a sulfated CXCR4 N-terminal peptide bound to dimeric CXCL12 [17]. CXCR4 can be 
sulfated at positions 7, 12, and 21. While each forms specific contacts with CXCL12, tyrosine 21 
corresponds to the conserved site of predicted sulfation. The structure of this complex revealed that the 
interface architecture involves both apolar and electrostatic contacts, which form a shallow cleft on the 
chemokine surface between the N-loop and β3 strand (Figure 1). In particular, the CXCL12 side chains 
of Val18, Arg47, and Val49 give rise to nuclear Overhauser effect (NOE) correlations with the ring of 
CXCR4  sTyr21  illustrating  that  the  sulfotyrosine  is  within  5  Å  of  these  residues.  We  recently 
demonstrated  that  small  molecules  binding  the  sTyr21  site  of  CXCL12  inhibit  the  functional 
interaction  between  chemokine  and  receptor  in  vitro.  This  demonstrates  that,  in  addition  to  their 
receptors, chemokines may themselves be legitimate targets for drug discovery [18]. Because both the 
N-terminal  tyrosine  and  the  chemokine  fold  are  highly  conserved,  we  hypothesized  that  a Int. J. Mol. Sci. 2011, 12                       
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sulfotyrosine-binding pocket analogous to the sTyr21 recognition site on CXCL12 may be present 
across the entire human chemokine superfamily. 
Figure 1. The CXCR4 sTyr21 binds to CXCL12 in a cleft formed by the N-loop and β3 
strand.  (A)  The  structure  of  CXCL12  (gray)  in  complex  with  the  N-terminus  of 
CXCR4 (salmon)  illustrates  that  the  architecture  of  the  sulfotyrosine  binding  pocket 
requires  both  apolar  and  charged  contacts  (PDB  2K05).  The  side  chains  of  CXCL12 
residues Val18, Arg47, and Val49 all provided intermolecular NOEs to the CXCR4 sTyr21 
residue-establishing the atoms are within 5 Å; (B) Surface representation underscores the 
presence of a binding cleft produced by the N-loop and β3 strand. 
 
To assess the likelihood that the chemokine family harbors a conserved sulfotyrosine binding site, 
we used a multiple sequence alignment to identify conserved residues in the vicinity of the sTyr21 
pocket. Next, we inspected 3D chemokine structures and ModBase models to identify sidechains at 
other  sequence  positions  that  could  substitute  for  differences  in  primary  sequence.  The  results 
suggested that a putative sulfotyrosine-binding pocket was present in nearly all human chemokines. To 
test whether sulfotyrosine could be used as a probe to confirm the pocket, we monitored sulfotyrosine 
binding to CXCL12, XCL1, CX3CL1, and CCL5 by nuclear magnetic resonance (NMR) spectroscopy. 
Mapping of the residues most perturbed by sulfotyrosine onto the protein structure confirmed that a 
conserved recognitions site was present in representative members of each chemokine subfamily. 
2. Methods 
2.1. Chemokine Multiple-Sequence Alignment 
Primary  amino  acid  sequences  of  all  human  chemokines  were  submitted  to  the  program 
ClustalW 2.1  to  generate  an  alignment  [19].  The  consensus  sequence  was  generated  using  the 
WebLogo server [20]. 
2.2. Chemokine Structures and Models 
Previously  determined  chemokine  structures  were  downloaded  from  the  RCSB  Protein  Data 
Bank (www.pdb.org) [21]. Models of unsolved chemokines were obtained from, and are freely available 
at, ModBase (http://modbase.compbio.ucsf.edu/modbase-cgi/index.cgi) [22] and Modweb [23]. Only Int. J. Mol. Sci. 2011, 12                       
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models with a MPQS score >1.1 were considered reliable for further analysis. The structures of all 
unsolved  chemokines  were  reliably  modeled  with  the  exception  of  CCL25,  CCL28,  CXCL16, 
and CXCL17. 
2.3. Structural Homology Modeling 
Structures of each chemokine subfamily were subjected to pair-wise analysis with a representative 
chemokine (CCL5, CXCL12, or XCL1) from each subfamily. As modeled chemokines possess only a 
single  solution,  each  NMR  ensemble  had  to  be  reduced  to  one  structure  for  alignment.  First,  an 
average structure was calculated using Molmol [24]; then, the RMSD between the mean structure and 
each member of the ensemble was  calculated.  The structure within the ensemble with  the lowest 
heavy-atom RMSD was selected as the mean structure for that chemokine. Pair-wise alignment was 
performed using the DaliLite-pairwise option (Version 3.1) of the Dali Server [25]. 
2.4. Protein Expression and Purification 
[U-
15N]-CXCL12  expression  and  purification  was  carried  out  as  previously  described  [26].  
[U-
15N]-XCL1cc3(1-93)  was  expressed  and  purified  as  previously  described  [27].  Expression  and 
purification of [U-
15N]-CCL5 and [U-
15N]-CX3CL1 were conducted as described previously [28]. 
2.5. NMR Analysis 
Each  sample  was  prepared  at  previously  published  solution  conditions  to  facilitate  assignment 
transfer.  Each  sample  contained  0.02%  (v/v)  NaN3  and  10%  (v/v)  D2O  as  the  lock  solvent.  The 
CXCL12 sample contained 250 μM [U-
15N]-CXCL12 in 25mM d-MES buffer (pH 6.8). [U-
15N]-CCL5 
was  dissolved  at  125  μM  in  50  mM  NaPO4  (pH  3.2).  250  μM  [U-
15N]-CX3CL1  was  prepared 
unbuffered at pH 3.6. 250 μM [U-
15N]-XCL1cc3 was prepared in 20 mM NaPO4 (pH 6.0). 
Sulfotyrosine (H-Tyr(SO3H)-OH; Bachem) was titrated from 0–100 mM in 10 mM increments and 
monitored by 2D 
1H-
15N heteronuclear single-quantum coherence (HSQC) spectroscopy experiments. 
NMR analysis was performed on a Bruker 600 MHz spectrometer equipped with a TXI triple-resonance 
cryoprobe. Experiments with CXCL12 were collected at 37 ° C and all other data were collected at 
25 ° C. Data was converted and processed using NMRPipe [29]. Previously published assignments for 
CXCL12 [26], CCL5 [30], XCL1 [27], and CX3CL1 [31] were transferred by visual inspection and 
chemical shift values were tracked using CARA [32]. Combined 
1H-
15N chemical shift perturbations 
were  calculated  as  ((5ΔʴH)
2  +  (ΔʴNH)
2)
0.5,  where  ʴH  and  ʴNH  are  the  amide  proton  and  nitrogen 
chemical shifts, respectively. 
3. Results and Discussion 
3.1. Chemokine Primary Sequence Alignment 
Primary protein sequence alignment is a classic method of probing evolutionary conservation and 
homology.  To  identify  regions  of  amino  acid  conservation  within  and  between  chemokine 
subfamilies, we  performed  a  multiple-sequence  alignment  of  all  43  human  chemokines  using Int. J. Mol. Sci. 2011, 12                       
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ClustalW 2.1  (Figure  2)  [19].  The  N-terminus  preceding  the  first  conserved  cysteine  is  highly 
disordered and the C-terminal helix orientation is dependent on solution condition and oligomeric 
state [33,34];  therefore,  only  the  amino  acids  comprising  the  beta  sheet  of  each  chemokine  were 
considered. The beta sheet residues were isolated by truncating the protein sequence prior to the first 
conserved cysteine and at the C-terminus following the conserved β3 cysteine. Amino acid positions 
will be hereafter referred to by their alignment position in Figure 2. 
Figure  2.  Primary  sequence  alignment  of  all  human  chemokines.  Multiple  sequence 
alignment was performed using ClustalW 2.1. The consensus sequence was generated from 
the WebLogo server [20]. 
 
The consensus sequence reveals little overall homology aside from the conserved cysteine residues, 
which  participate  in  structurally  essential  disulfide  crosslinks.  Conservation  at  a  few  other 
locations (e.g., proline at position 13, apolar residues at positions 23 and 40–42) may also preserve 
key structural features. However, conservation of apolar residues at the 13, 20 and 62 positions, may 
contribute  to  a  common  sulfotyrosine  recognition  site.  The  beta-branched  hydrophobic  residue  at 
position  13  corresponds  to  Val18  in  the  CXCL12  N-loop,  which  contacts  the  phenyl  ring  of 
sTyr21 (Figure 1). The residue at position 20 in CXCL12, Val23, does not directly contact the CXCR4 
sulfotyrosine  but  does  contact  Val49  a  key  residue  in  this  cleft,  which  corresponds  to Int. J. Mol. Sci. 2011, 12                       
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sequence position 62. Further, all C, CC, CX3C, and 70% of CXC chemokines possess an apolar 
amino acid at position 62. 
Examination of the alignment does not reveal strict conservation of polar contacts such as Arg47 
from  CXCL12.  However,  the  presence  of  other  positively  charged  residues  in  adjacent  positions, 
between  positions  45  and  59,  suggests  homologous  electrostatic  interactions.  For  example,  21  of  
24  CC  chemokines,  50%  of  CXC  chemokines,  and  CX3CL1  maintain  a  basic  residue  at  the  
position 60—analogous to CXCL12 Arg47. 
3.2. Homology Modeling 
Experimental structures have been determined for 28 of the 43 known human chemokines by NMR 
or X-ray crystallography. In order to compare the three-dimensional structural conservation across all 
chemokines, the structures of unsolved chemokines had to first be modeled. The servers Modweb and 
Modbase provide protein structure predictions based on a FASTA query sequence [23]. The reliability 
of all models is based on the MPQS value, which is a composite score comprised of sequence identity 
to the template, target coverage of the template, and three individual scores. The three scores E-value, 
Z-dope, and GA341 relate to the significance of the alignment between the target and the template, 
shape of the structure, and fold, respectively. Only models with a reliable MPQS score, >1.1, were 
used for subsequent analysis; if a chemokine had several reliable models, the version with the highest 
MPQS score was selected. This methodology provided 3D structures of all human chemokines except: 
CCL25, CCL28, CXCL16, and CXCL17 (Table 1). Examination of the template structure for each 
model reveals that chemokines of the same subfamily resulted in the highest scoring model except in 
the case of CCL18, CCL19, and CCL22 which all utilized a viral chemokine (PDB 1ZXT). 
Table 1. A list of all human chemokine structures used. The Protein DataBank (PDB) 
accession number for all chemokines is listed in Table 1(a). Chemokines in Table 1(b) 
were  modeled  from  the  indicated  template  PDB  structures  and  are  available  from  the 
ModBase  Database using the  Accession  ID. The MPQS  score is  a composite score to 
describe the model quality, generally scores ≥1.1 are reliable. Statistics from pair-wise 
alignment  for  each  chemokine  against  a  representative  from  its  subfamily  (CCL5, 
CXCL12, and XCL1) are summarized by the Dali Z-score (values ≥2.0 are reliable), Cʱ 
RMSD, and percent sequence identity. CX3CL1 was aligned against CXCL12. 
(a) 
Chemokine  PDB ID  Dali Z-score  Cα RMSD (Å)  Sequence 
Identity (%) 
XCL Subfamily 
XCL 1 
CCL Subfamily 
2HDM       
CCL1   IEL0  3.6  2.3  30 
CCL2  1DOM  5.6  1.3  25 
CCL3   QB53  5.3  1.6  50 
CCL4  1HUM  5.4  1.7  55 
CCL5  1HRJ       Int. J. Mol. Sci. 2011, 12                       
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Table 1. Cont. 
Chemokine  PDB ID  Dali Z-score  Cα RMSD (Å)  Sequence 
Identity (%) 
CCL7  1BO0  5.1  1.5  28 
CCL8  1ESR  5.8  1.5  33 
CCL11  1EOT  5.1  1.5  30 
CCL13  2RA4  5.8  1.5  28 
CCL14  2Q8T  6.1  1.3  40 
CCL15  2HCC  5.3  1.5  50 
CCL17  1NR4  5.6  1.5  38 
CCL20  2JYO  5.7  1.4  30 
CCL23  1G91   5.3  1.5  40 
CCL24  1EIG  5.1  1.6  28 
CCL26  1G2S  5.8  1.5  43 
CCL27  2KUM  4.0  2.0  21 
CXCL subfamily         
CXCL1  1MSG  2.1  2.8  14 
CXCL2  1QNK  5.2  2.0  20 
CXCL4  1F9A  4.8  1.9  26 
CXCL7  1NAP  5.2  1.8  23 
CXCL8  1ILQ  4.0  2.0  21 
CXCL10  1LV9  3.7  2.6  15 
CXCL11  1RJT   1.7  2.6  9 
CXCL12  2KEE       
CXCL14  2HDL  4.6  2.6  20 
CX3CL subfamily         
CX3CL1  1B2T  4.0  2.3  18 
(b) 
Chemokine  Mod Base 
ID 
Template PDB  MPQS 
Score 
Dali Z-score  Cα RMSD (Å)  Sequence 
Identity (%) 
XCL subfamily             
XCL2  Q9UBD3  1J8I (XCL1)  1.85  5.1  1.2  97 
CCL subfamily             
CCL16  O15467  2Q8R (CCL4)  1.16  5.6  1.1  41 
CCL18  P55774  1ZXT (viral)  1.40  5.6  1.1  35 
CCL19  Q99731  1ZXT (viral)  1.21  5.4  1.5  33 
CCL21  O00585  1ESR (CCL8)  1.11  4.8  1.5  33 
CCL22  O00626  1ZXT (viral)  1.25  5.6  1.5  33 
CXCL subfamily             
CXCL3  P19876  1QNK (CXCL2)  1.70  4.7  2.0  18 
CXCL5  P42830  1TVX (CXCL7)  1.27  5.0  1.9  23 
CXCL6  P27784  1TVX (CXCL7)  1.22  4.4  1.8  26 
CXCL9  Q07325  1GNK(CXCL2)  1.18  4.8  1.8  28 
CXCL13  Q43927  3IL8(CXCL8)  1.26  4.3  1.9  26 
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3.3. Structural Alignment 
Chemokines are known to adopt a canonical fold comprised of a three-stranded beta sheet followed 
by an alpha helix. Chemokines all activate G protein-coupled receptors and therefore may possess 
structural homology at the ligand:receptor interface. Previously determined chemokine structures and 
modeled chemokines were aligned using the Dali server. Pair-wise alignment was performed in each 
subfamily against a representative chemokine: CCL5, CXCL12, and XCL1. As CX3CL1 is the only 
CX3C family member, it was aligned against CXCL12. The quality of each alignment is assessed by a 
Dali Z-score, Cʱ RMSD, number of aligned residues, and percent sequence identity (Table 1) [35]. In 
general, each chemokine sequence was aligned over approximately 42 residues with 40 structurally 
equivalent residues. As the chemokine fold is highly conserved, it is not surprising that sequence 
identities between 14–55% still resulted in average backbone RMSD = 1.5–2.0 Å (Figure 3A). With 
the exception of CXCL11, all alignments resulted in a Z-score ≥ 2.0 indicating a significant degree of 
homology [36]. Overall, the lowest Z-scores can be correlated to poor sequence identity, such as the 
9% identity between CXCL11 and CXCL12. 
Visual inspection of the residues surrounding the putative pocket identified several potential polar 
contacts for sulfotyrosine coordination. As identified in the primary sequence alignment, 28 of the 
39 human chemokine examined possess a basic residue at position 60; in all of corresponding structures 
this amino acid points toward the binding pocket for potential sulfate coordination (Figure 3B). The 
other  11  family  members  possess  three  varieties  of  structural  features  capable  of  rectifying  this 
deficiency.  Both  XCL1  and  XCL2  contain  an  Arg  at  position  51  that  is  directed  toward  the  
N-loop (Figure 3C). Five chemokines (CXCL2, CXCL9, CCL20, CCL21, and CCL24), which do not 
possess basic residues in the third beta strand, do maintain charged amino acids properly oriented in 
the N-loop (Figure 3D). CXCL11 and CXCL14 contain additional residues in β3 that pucker and allow 
basic residues at positions 52 and 49, respectively, to orient toward the putative pocket (Figure 3E). 
The turn between β2 and β3 of two CXC (CXCL10 and CXCL13) and three CC (CCL20, CCL21, and 
CCL24)  chemokines  contain  several  basic  residues  that  are  not  optimally  oriented  in  the  current 
structures but could conceivably rearrange during receptor binding. 
In addition to polar contacts, sulfotyrosine recognition also relies on hydrophobic interactions. The 
CXCR4 sTyr21 residue forms contacts with both CXCL12 Val18 and Val49 [17]. Primary sequence 
and structural alignment reveals strong conservation of apolar residues in the N-loop of all chemokines 
particularly at the position corresponding to CXCL12 Val18 (position 13). Furthermore, 35 of the 
39 human  chemokines  possess  a  hydrophobic  residue  at  position  62  (Figure  2)  corresponding  to 
CXCL12 Val49. Of the chemokines lacking this apolar amino acid in the β2 strand, CXCL9, CXCL10, 
and CXCL11 all maintain a non-polar residue (position 44) at the end of the β2 strand that could serve 
in its place; qualitatively, this apolar β2 residue is conserved throughout the CXC subfamily but exists 
primarily as a threonine in the rest of the chemokine family. Only CXCL14 is unique in that it does not 
contain corresponding residues to replace the hydrophobic β3 contact, but the functional target of this 
orphan  chemokine  remains  unknown  and  may  not  rely  on  sulfotyrosine  recognition.  Overall,  our 
results identify positively charged and apolar residues in the third beta strand and N-loop that are 
present in all human chemokine subfamilies suggesting a conserved sulfotyrosine binding pocket. 
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Figure 3. Chemokines maintain polar residues oriented toward the putative sulfotyrosine 
cleft. (A) Dali structural alignment for each chemokine subfamily, from top to bottom: C, 
CXC, CC, and CX3C chemokines. Polar residues oriented toward the putative binding 
pocket originate from four different positions; (B) 70% of the structures analyzed possess a 
basic residue at position  60, illustrated by CXCL12 Arg47; (C) Arginine  43 of the  C 
chemokines,  located  at  position  51,  is  oriented  toward  the  cleft;  (D)  Several  CC 
chemokines, CCL20 shown here, have basic residues in the N-loop positioned toward the 
binding  cleft;  (E)  CXCL14  contains  a  G1  β-bulge  in  the  β3  strand  positioning 
Arg41 (position 49) toward the putative sulfotyrosine binding pocket. 
 
3.4. Sulfotyrosine Titration Identifies CXCL12 sTyr21 Binding Pocket 
The CXCR4 receptor is sulfated at three tyrosine residues that bind distinct locations of CXCL12. 
To  test  whether  sulfotyrosine  alone  could  act  as  a  probe  for  the  CXCL12  binding  pockets,  we 
monitored  a  titration  using  2D 
1H-
15N  HSQC  spectroscopy.  HSQC  spectral  overlays  (Figure  4A) 
demonstrate  significant  chemical  shift  perturbations  in  the  chemokine.  The 
1H-
15N  chemical  shift 
perturbations were calculated and mapped onto the surface of CXCL12 previously solved at identical 
solution conditions in the absence of sulfotyrosine (PDB 2KEE; Figure 4B). The most significant 
chemical shift perturbations (purple) correspond to residues Arg12, Arg40, Gln48 and Val49, which 
border  the  CXCR4  sTyr21  binding  pocket.  These  residues  were  previously  identified  by  HSQC 
titration experiments in which the chemical shift difference between a sulfated and unsulfated CXCR4 
peptide was used to identify the binding site [37]. The large chemical shift perturbations in residues 
His25 and Lys27  are consistent with the CXCR4 sTyr12 binding site. In the structure of dimeric 
CXCL12 bound to a triply-sulfated CXCR4 peptide, sTyr7 makes contacts with Val23 of the adjacent Int. J. Mol. Sci. 2011, 12                       
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protomer  suggesting  a  unique  site  on  the  CXCL12  monomer.  At  these  experimental  conditions 
CXCL12 exists in an equilibrium highly favoring the monomer, but sulfotyrosine addition did not 
produce any chemical shift perturbations suggestive of a monomeric CXCL12/sTyr7 binding pocket. 
Our  results  suggest  that  this  assay  is  capable  of  identifying  sulfotyrosine-binding  pockets  in  
other chemokines. 
Figure  4.  Sulfotyrosine  can  probe  the  CXCL12  sTyr21-binding  pocket.  (A)  Overlay 
of HSQC  spectra  of  CXCL12  in  the  presence  of  0  mM  (black),  10  mM  (gray),  and  
30 mM (green) sulfotyrosine; (B) The change in the 
1H-
15N chemical shift was calculated 
and  plotted  as  a  function  of  CXCL12  residue  number.  Residues  with  the  largest 
perturbations  were  mapped  onto  the  CXCL12  structure  and  localize  to  the  CXCR4  
sTyr21-binding cleft. 
 
 
3.5. Sulfotyrosine Probe Highlights Similar Pocket in XCL1, CCL5 and CX3CL1 Chemokines 
Chemokine representatives of the C, CC, and CX3C chemokine were titrated with sulfotyrosine in 
10 mM increments from 0 to 100 mM and monitored by 2D HSQC. The displayed chemical shift 
values  were  measured  at  30  mM  sulfotyrosine  as  higher  concentrations  resulted  in  pronounced  
non-specific perturbations as specific sites began to saturate. Similar to the titration of CXCL12, all 
three chemokines contained a subset of residues located primarily in the N-loop and β3 strand that 
displayed large chemical shift perturbations relative to the rest of the protein (Figure 5). 
XCL1 is known to exist in a monomer-dimer equilibrium under physiological conditions, but only 
the  monomeric  form  is  capable  of  binding  XCR1  [27].  Using  a  constitutively-locked  monomer, 
XCL1cc3(1–93), we identified five residues (Ser13, Arg18, Arg23, Ile24, and Arg43) significantly 
perturbed by sulfotyrosine (Figure 5A). Our results support a sulfotyrosine binding pocket similar to 
CXCL12 in the cleft between the N-loop and β3 strand; however, there is currently no structural or 
mutagenic data mapping the XCR1 N-terminal binding site to confirm our results.  
 Int. J. Mol. Sci. 2011, 12                       
 
 
3750 
Figure  5.  Sulfotyrosine  localizes  to  the  cleft  between  the  N-loop  and  β3  strand.  The 
difference in 
1H-
15N chemical shift in the absence and presence of 30mM sulfotyrosine 
were plotted as a function of residue number for XCL1, CX3CL1, and CCL5. In general, 
the  residues  with  the  largest  perturbations  (colored  spheres)  localize  to  the  putative 
sulfotyrosine-binding cleft. (A) XCL1 had the largest chemical shifts in residues Ser13, 
Arg18, Arg43, and Val47; (B) CX3CL1 residues Lys18, Ile19, Val21, Ala22, Gln31, and 
Leu48 displayed the most significant chemical shift perturbations; (C) The chemical shifts 
in CCL5 also localized to the N-loop and β3 strand including residues Val3, His23, Lys45, 
Arg47, and Gln48. 
 
Sulfotyrosine titration produced significant perturbations in CX3CL1 residues Lys18, Ile19, Val21, 
Ala22,  Gln31,  and  Leu48,  which,  with  the  exception  of  Gln31,  cluster  to  the  N-loop  and  β3 
strand (Figure 5B). Titration of CX3CL1 with a CX3CR1 (1–19) peptide previously identified a role 
for Gln31 and Leu48 in N-terminus binding [31]. Mutagenesis experiments further illustrated a modest 
role for Lys18 in which a Glu substitution reduced affinity for CX3CL1 20-fold [38]. No mutagenesis 
experiments have specifically probed apolar residues in the putative binding cleft; however, our data 
suggests a critical role for these residues. 
Although known to exist in a monomer-dimer equilibrium at low pH, the CCL5 spectrum contained 
only dimeric resonances consistent with the previously reported Kd = 35 μM [39]. Residues His23, 
Lys45, and Arg47 identified in our titration were previously shown to exhibit large chemical shift 
perturbations in the presence of a CCR5 N-terminal peptide sulfated at residues Tyr10 and Tyr14 
(Figure 5C) [40]. 
4. Conclusions 
The prevalence of both receptor tyrosine O-sulfation and the ubiquitous chemokine fold suggests 
the  possibility  of  a  conserved  sulfotyrosine-binding  site.  In  the  extracellular  N-terminus  of  most 
chemokine receptors, a tyrosine is present approximately ten residues away from a highly conserved 
cysteine  [9,16]  (e.g.,  Tyr21  of  CXCR4).  Using  the  CXCL12/CXCR4  complex  as  a  guide,  our Int. J. Mol. Sci. 2011, 12                       
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structure-based homology analysis suggested that only the recognition site for sTyr21 is likely to be 
conserved in other chemokines. The sTyr21-binding cleft is located between the N-loop and β3 strand, 
which possesses both polar and hydrophobic contacts. This pocket, termed the chemokine groove, has 
been previously identified as a key mediator of receptor binding in CC, CX3C, and CXC subfamilies 
through mutagenesis and NMR binding experiments [31,41–47]. Overall, our analysis revealed few 
globally conserved sequence positions beyond the structurally essential cysteine residues located in the 
N-terminus  and  β3  strand  that  distinguish  the  four  chemokine  subfamilies  [48].  However,  several 
apolar  and  basic  residues  were  found  to  cluster  in  and  around  the  sulfotyrosine-binding  pocket. 
Members from  all four subfamilies,  composing more than 70% of chemokines,  possessed a basic 
residue at position 60. Further, 90% of all human chemokines possess an apolar residue at position 62. 
Structural  alignment  not  only  confirmed  the  proper  orientation  and  spatial  position  of  residues 
identified  by  primary  sequence  alignment,  but  revealed  compensatory  amino  acids  in  chemokines 
where the key sulfotyrosine recognition residues were not conserved. Absence of a basic residue at 
position  60  was  remedied  mainly  through  three  alternative  mutations.  Most  of  the  chemokines 
contained arginine or lysine residues at other positions within the β3 strand that position toward the 
pocket; several proteins also contained charged amino acids in the β2-β3 turn. The other deficient 
proteins, including CCL20, CCL21, and CCL24 all contain positively charged residues in the N-loop 
oriented toward the binding cleft. Indeed, CCL24 Arg15 experiences complete line broadening in an 
NMR titration with a CCR3 N-terminal peptide suggesting that this residue participates directly in 
receptor binding [49]. CCL25, CCL28, CXCL16, and CXCL17, which lack experimentally determined 
structures,  could  not  be  modeled  due  to  low  sequence  homology  with  other  family  members. 
Interestingly, all four proteins still retain an apolar residue at position 62, and three of them (all except 
CXCL16) possess a basic residue at site 58 or 60 suggesting the presence of a cleft compatible with 
sulfotyrosine binding.  
The problem of identifying the receptor sulfotyrosine binding pocket on chemokines has usually 
been solved by titrating sulfated  peptides  representing the  N-terminal fragment of the  receptor of 
interest into a chemokine sample and monitoring backbone amide chemical shift changes by HSQC 
NMR [37,40–42,49,50]. Several methods, such as solid-phase synthesis [50,51] and in vitro enzymatic 
sulfation  [17,37,52],  have  been  utilized  to  sulfate  these  peptides.  However,  these  techniques  are 
challenging due to low yields, the labile nature of the sulfate modification, and difficulties associated 
with separating complex mixtures of products. In an effort to produce a simpler probe, we titrated 
CXCL12, CCL5, CX3CL1, and XCL1 with free sulfotyrosine (H2N-Tyr(SO3)-CO2). These proteins 
were chosen as representatives of each subfamily because the binding site of each chemokine, with the 
exception of XCL1, had previously been probed with receptor peptides [31,37,38,40]. Each protein 
exhibited localized chemical shift perturbations in the chemokine groove correlating with previous 
peptide binding studies. In addition, although no XCL1/XCR1 binding information is published, the 
localization of perturbations to the analogous cleft suggests a similarly conserved sulfotyrosine-binding 
site. Interestingly, the strong perturbation in CCL5 Tyr3 suggests sulfotyrosine is a powerful probe for 
binding pocket identification regardless of whether the chemokine is in the native oligomeric state for 
receptor binding. Tyr3 is only located near the sulfotyrosine pocket when CCL5 is dimeric; however, 
only monomeric CCL5 interacts with the CCR5 N-terminus [40]. Although the sulfotyrosine probe 
binds  too  weakly  (Kd  ~10
−2  M)  for  structural  characterization,  these  results  suggest  that  short Int. J. Mol. Sci. 2011, 12                       
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sulfopeptides, which should be easier to produce, may possess sufficient specificity and affinity to 
enable structure determination by NMR [53]. 
Identification of specific sulfotyrosine binding pockets on chemokines could define a new category 
of  targets  for  structure-based  drug  discovery.  Currently,  only  a  single  chemokine/sulfopeptide 
structure, CXCL12/CXCR4, has been determined [17]. Using this structure we recently performed a 
high-throughput computational docking study to identify small molecules with the propensity to bind 
the sTyr21 site. The top ranking candidate ligands were then tested for binding by NMR, and one 
compound with a 64 μM affinity was found to inhibit CXCR4-mediated calcium flux signaling of 
THP-1  monocytes  [18].  Similar  docking  studies  against  the  XCL1  site  defined  by  sulfotyrosine 
chemical  shift  mapping  have  identified  small  molecule  ligands  that  bind  the  target  site  and  are 
currently being tested for inhibition of XCL1/XCR1 interactions [54]. 
Overall,  our  results  show  that  the  chemokine  superfamily  possesses  a  conserved  sulfotyrosine 
binding site, critical for high-affinity interactions that can potentially be targeted for the design of 
specific or broad-spectrum inhibitors. Since the discovery of the first chemokine, CXCL8, almost 
25 years ago a total of 43 human chemokines have been identified. As only three new chemokines 
have been isolated in the last decade [48], it is generally believed that most human chemokines have 
been discovered. Thus, we conclude that the chemokines lacking a potential sulfotyrosine recognition 
site represent exceptions to the general rule. The chemokines and their receptors are broadly expressed 
and relatively promiscuous with two or more partners in most cases. As a consequence, inhibitors 
targeting  a  specific  receptor  may  not  have  the  optimal  specificity,  since  they  may  interfere  with 
signaling of multiple chemokine ligands, or a second receptor could coordinate chemotaxis toward a 
given site of chemokine secretion. If the chemokine ligands can instead be inhibited by blocking the 
sulfotyrosine-mediated  receptor  interaction,  novel  inhibitors  might  be  designed  with  favorable 
therapeutic properties. In addition, high-affinity ligands could also be adapted for use as diagnostic 
molecules  for  imaging  of  chemokine  levels  in  either  research  or  clinical  settings.  Although  the 
structural similarities outlined in this article and elsewhere suggest that sulfotyrosine-directed selective 
blocking of individual chemokines could be challenging, the potential for identifying broad-spectrum 
inhibitors represents a powerful complementary strategy. 
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